RIT1

Across TCGA pan-cancer cohorts, RIT1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RIT1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where RIT1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RIT1 is over-expressed in tumor, although a few such as LUAD and CCRCC show the opposite, repressed pattern.

LUAD, CCRCC, and LSCC are the cancer types where RIT1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RIT1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	All	−0.584	<.001	9	view →
CCRCC	All	III,IV	−0.241	<.001	9	view →
LSCC	Male	All	−0.538	<.001	8	view →
HNSC	Male	All	−0.261	<.001	6	view →
OV	All	All	−0.630	<.001	2	view →
COAD	Female	III,IV	−0.570	.019	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RIT1–LUAD

Open the LUAD breakdown →